Coulter Partners was delighted to partner recently with Stilla Technologies, provider of pioneering digital PCR (dPCR) solutions for high-precision genetic analysis, to secure the appointment of Khaled Bahi as Chief Financial Officer. His appointment comes at a time of rapid growth for the company, with the recent opening of a U.S. subsidiary headquartered in Beverly, Massachusetts, providing American customers with direct sales and support, including a demo lab and training center.
EVENTS
4 March
2020
The BIA's Women in Biotech series returns to London in March, scheduled for the same week as International Women’s Day 2020. Meet us then for an excellent evening of networking and thought-provoking discussion.
Coulter Partners was very pleased to partner once again with OxStem Limited to secure the appointment of Dr. Ian Churcher to the role of Chief Scientific Officer.
Ian Churcher has 22 years’ experience in pharmaceutical R&D obtained in positions of increasing seniority in international companies including Merck Sharp & Dohme (Merck), GlaxoSmithKline (GSK) and BenevolentAIEVENTS
12 March
2020
Coulter Partners is delighted to be sponsoring BioCapital Europe, organised by LSP (Life Sciences Partners) once again in 2020. The 18th consecutive event will take place on 12th March in Amsterdam, The Netherlands. For the 9th year running, the event will be held at the luxurious and historic hotel Sofitel Legend The Grand Amsterdam, the former town hall situated in the heart of Amsterdam.
Coulter Partners was delighted to partner once again with innovative nanoparticle medicine enabling company, Nanoform to secure the appointment of Sally Langa as Head of US Sales. The new role will enable Nanoform to continue its rapid growth with a strengthened presence in the US market.EVENTS
12 March
2020
AESC's Executive Research Forums are the premier events for executive research professionals to stay at the forefront of best practices, leverage new strategic insights and stay at the top of the profession.
A selection of senior appointments during Quarter 3, 2019 across EMEA. Industry segments this quarter included Artificial Intelligence, CNS, Animal Health, Immunology, Gene Therapy, Diagnostics, Precision Medicine, Vaccines and Antimicrobials.EVENTS
18 March - 19 March
2020
The World Pharma Pricing and Market Access Congress is Europe’s largest market access and pricing conference. Bringing together industry leaders from pharma companies, payers and HTAs, PPMA provides excellent opportunities to hear from patient led organisations, healthcare providers and other industry bodies.
EVENTS
23 March - 25 March
2020
Coulter Partners was delighted to partner recently with Azitra Inc. and secure the appointment of Mark Sampson, Ph.D. as their Chief Scientific Officer. Azitra is a clinical-stage medical dermatology company addressing severe skin conditions by harnessing the microbiome and has just announced that it has closed a $14 million Series A financing, led by KdT Ventures in conjunction with existing investor Bios Partners. 
Edward Hæggström, CEO of Nanoform said: “It gives me great pleasure to welcome Mads Laustsen to the Nanoform board. Mads is an exceptional entrepreneur with vast experience in the provision of GMP facilities and infrastructures. His outstanding experience will be incredibly valuable as we expand our manufacturing capacity and I thank the highly professional team at Coulter Partners for helping us once more to achieve such a quality appointment.”
On June 25, Coulter Partners hosted around 200 guests for a sparkling Summer Party in the beautiful gardens of the Walks, Gray’s Inn, London. International clients and colleagues joined the London team in the big marquee to celebrate a fabulous year!
“We are pleased that Ms. Beelen has joined Incysus at this key phase of development and thank the team at Coulter Partners for their outstanding professional support in achieving this appointment,” said William Ho, Chief Executive Officer of Incysus. “Melissa’s more than two decades of experience in drug development and clinical research will be invaluable as we take the next steps to develop commercially viable and effective allogeneic cellular immunotherapies for the treatment of cancer.”
In April Samantha Bower and Mat Rosso, two of Coulter Partners’ Pittsburgh team, ran far from home in their first London Marathon in aid of London based charity, Kith and Kids. Samantha came home in a truly athletic 2 hours and 57 minutes and was the 81st woman to cross the line!!! In his first ever marathon, former US professional figure skater, Mat completed the race in 4 hours and 40 minutes.
OxStem Co-Founder, Director and Waynflete Professor of Chemistry at the University of Oxford, Professor Steve Davies, said: “On behalf of the Board, Founders and management team, we warmly welcome Dr Stuart Collinson to OxStem and I thank the team at Coulter Partners for their outstanding professional support in achieving this appointment. Stuart is a highly experienced international business leader who brings significant fundraising, product development, partnering and commercialisation experience. We look forward to working with him to develop transformative medicines for patients suffering from severe degenerative diseases."
Global Life Sciences search specialist, Coulter Partners is pleased to announce the opening of a new office in Paris and another 14 appointments worldwide, during an extremely successful year which has seen group sales grow by 31%. Business in the US has grown by 165% since last year and this region now accounts for 45% of group sales.
“We were delighted to work once more with Coulter Partners to identify Christa and bring her into Pivot Bio. Her experience is a great addition to our already strong leadership team,” said Karsten Temme, CEO and co-founder, Pivot Bio. “Christa will play a key role in Pivot’s growth as we expand the technology to new markets.”
Dr John Ford, CEO, Enterprise Therapeutics, said: “We are delighted that Amit has chosen to join as Chairman at this exciting time for the Company, as we prepare to take our two lead programmes into the clinic in the next 12 months. Amit brings a wealth of experience in product development, portfolio management and commercial strategy in both the US and EU that will be critical in driving the Company through the next phase of its development. I would like to thank the team at Coulter Partners for their outstanding professional support in achieving this high calibre appointment.”